Rethinking pharmaceutical development: A not-for-profit model to address global health inequities

Area of Science:

• Pharmaceutical Sciences
• Global Health Equity
• Health Economics

Background:

• Modern pharmaceuticals are scientific and economic triumphs, yet significant access inequities remain.
• Market-driven models excel with strong commercial incentives but neglect diseases with limited market potential, such as neglected tropical diseases.
• This disparity particularly affects low- and middle-income countries (LMICs).

Purpose of the Study:

• To analyze the root causes of inequity in the current pharmaceutical access system.
• To explore the potential and role of not-for-profit pharmaceutical development.
• To advocate for a new, complementary model prioritizing public health over market returns.

Main Methods:

• System analysis of pharmaceutical market dynamics.
• Review of traditional and non-profit drug development models.
• Examination of access barriers in LMICs.

Main Results:

• Current pharmaceutical models inherently create access inequities by prioritizing profitable markets.
• Diseases predominantly affecting populations in LMICs, like neglected tropical diseases, are systematically underserved.
• Not-for-profit initiatives offer a partial solution but require integration into a broader strategy.

Conclusions:

• The existing pharmaceutical system requires fundamental reform to address global health inequities.
• A complementary model focusing on public health needs, rather than solely market profitability, is essential.
• Urgent implementation of such a model is critical for achieving equitable access to essential medicines worldwide.